Profile data is unavailable for this security.
About the company
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.
- Revenue in USD (TTM)27.81bn
- Net income in USD1.05bn
- Incorporated1987
- Employees18.00k
- LocationGilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
- Phone+1 (650) 574-3000
- Fax+1 (650) 578-9264
- Websitehttps://www.gilead.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | 9.67bn | 1.16bn | 28.87bn | 7.57k | 24.97 | 1.82 | 16.70 | 2.99 | 7.94 | 7.94 | 66.42 | 109.05 | 0.3723 | 1.23 | 4.60 | 1,277,675.00 | 4.46 | 12.53 | 5.07 | 14.83 | 75.54 | 83.04 | 11.97 | 26.93 | 1.48 | 2.87 | 0.2837 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Zoetis Inc | 8.92bn | 2.34bn | 88.67bn | 14.10k | 38.32 | 17.88 | 31.17 | 9.95 | 5.11 | 5.11 | 19.42 | 10.94 | 0.6388 | 1.04 | 6.59 | 632,269.50 | 16.78 | 14.47 | 19.23 | 17.18 | 70.03 | 69.77 | 26.27 | 25.77 | 2.09 | 16.74 | 0.5696 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Bristol-Myers Squibb Co | 46.51bn | -6.54bn | 100.34bn | 34.10k | -- | 5.90 | 28.68 | 2.16 | -3.26 | -3.26 | 22.83 | 8.39 | 0.4944 | 4.07 | 4.98 | 1,363,900.00 | -6.94 | 3.05 | -9.03 | 3.76 | 76.18 | 76.13 | -14.04 | 7.69 | 1.02 | 14.60 | 0.7543 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Gilead Sciences, Inc. | 27.81bn | 1.05bn | 103.40bn | 18.00k | 101.39 | 5.66 | 27.27 | 3.72 | 0.8191 | 0.8191 | 22.20 | 14.67 | 0.4797 | 3.43 | 6.25 | 1,544,722.00 | 1.78 | 6.74 | 2.26 | 8.12 | 77.44 | 79.14 | 3.71 | 16.95 | 0.9546 | 9.36 | 0.562 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Pfizer Inc | 55.64bn | -2.59bn | 169.04bn | 88.00k | -- | 1.93 | 40.89 | 3.04 | -0.4643 | -0.4646 | 9.81 | 15.48 | 0.255 | 1.47 | 5.15 | 632,295.40 | -1.17 | 8.20 | -1.43 | 10.40 | 71.29 | 69.34 | -4.61 | 22.68 | 0.602 | -- | 0.4412 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 30.93bn | 3.13bn | 178.82bn | 26.70k | 57.29 | 30.17 | 21.80 | 5.78 | 5.81 | 5.81 | 57.47 | 11.03 | 0.3415 | 1.75 | 4.85 | 1,158,577.00 | 3.46 | 10.36 | 4.39 | 13.06 | 63.30 | 75.41 | 10.12 | 26.51 | 0.8928 | 1.59 | 0.9136 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 109.55m | 8.80% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 78.31m | 6.29% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 76.25m | 6.13% |
| Capital Research & Management Co. (Global Investors)as of 30 Jun 2024 | 60.43m | 4.85% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 59.33m | 4.77% |
| Dodge & Coxas of 30 Jun 2024 | 33.12m | 2.66% |
| Geode Capital Management LLCas of 30 Jun 2024 | 26.97m | 2.17% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 21.73m | 1.75% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 17.39m | 1.40% |
| BlackRock Advisors (UK) Ltd.as of 30 Jun 2024 | 14.82m | 1.19% |
